Endeveco started the spin-off company with the sole purpose of bringing 710GO to market. Image credit: Shutterstock / Studio Romantic.

Endevica Bio has launched a new spin-off company, Abisati, to accelerate its obesity candidate into clinical trials.

The candidate, 710GO, is a peptide spun out of Endevica Bio’s platform of experimental drugs. Abisati aims to initiate a Phase I trial of the candidate in the second half of 2025, and the company will exclusively exist to bring 710GO to the market.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

710GO leverages the melanocortin system to induce weight loss, both alone and in combination with GLP1s. Endevica Bio’s studies have shown the drug is safe and effective in obese monkeys and rats.

In preclinical studies, 710GO led to a body weight loss of 7.5% in obese monkeys in one month relative to a control group. The monkey study also showed a steady 20% decrease in daily caloric intake. The study also found the treated monkeys consumed more high-fibre, low-fat foods.

CEO of Endevica Bio and Abisati, Russell Potterfield, said: “We are so excited about the prospects for a drug that could be life-changing for millions of people suffering from obesity. Our peptide has the potential to help patients lose weight without the side effects such as nausea and vomiting seen with drugs now on the market and without the ‘bounce back’ weight gain that can happen after patients discontinue medication.”

Endevica Bio discovered 710GO’s potential use in weight loss while researching a peptide to prevent involuntary weight loss associated with cachexia.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The weight loss field is heavily dominated by glucagon-like peptide 1 receptor agonists (GLP-1ra’s), with Eli Lilly’s tirzepatide and Novo Nordisk’s semaglutide being the frontrunners. Semaglutide, marketed at Ozempic for type 2 diabetes (T2D) and Wegovy for obesity, is predicted to raise $42.85bn in sales in 2030, according to GlobalData. Meanwhile, Eli Lilly’s candidate, marketed as Mounjaro for T2D and Zepbound for obesity, is predicted to bring in £57.65bn in the same year.

GlobalData is the parent company of the Clinical Trials Arena.

Both Lilly and Novo are investigating their candidates beyond T2D and obesity, with both having recently reported cardiovascular benefits to their drugs. Last week, Novo Nordisk announced semaglutide to be an effective treatment for metabolic dysfunction-associated steatohepatitis (MASH).